CN Patent

CN113713090B — 骨质疏松症的治疗

Assigned to Entera Bio Ltd · Expires 2023-06-02 · 3y expired

What this patent protects

本文涉及骨质疏松症的治疗，具体提供了通过口服施用组合物用于治疗骨质疏松症的药物组合物。所述组合物包含甲状旁腺激素或其片段；和SNAC(8‑N‑(2‑羟基苯甲酰)氨基辛酸钠)。还公开了所述组合物在制备药剂中的用途以及使用所述组合物治疗骨质疏松症的方法。

USPTO Abstract

本文涉及骨质疏松症的治疗，具体提供了通过口服施用组合物用于治疗骨质疏松症的药物组合物。所述组合物包含甲状旁腺激素或其片段；和SNAC(8‑N‑(2‑羟基苯甲酰)氨基辛酸钠)。还公开了所述组合物在制备药剂中的用途以及使用所述组合物治疗骨质疏松症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN113713090B
Jurisdiction
CN
Classification
—
Expires
2023-06-02
Drug substance claim
No
Drug product claim
No
Assignee
Entera Bio Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.